WALTHAM, Mass.

马萨诸塞州沃尔瑟姆

,

，

July 22, 2026

2026年7月22日

/PRNewswire/ -- Mentari Therapeutics, Inc. ('Mentari'), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors. The proceeds from the private placement will enable the continued development of Mentari's pipeline of targeted biologics aimed at improving outcomes for people living with migraines..

/美通社/ -- 专注于开发偏头痛预防疗法的私营生物技术公司 Mentari Therapeutics, Inc.（“Mentari”）今日宣布，向领先的健康care投资者完成2亿美元的私募配售。此次私募配售所得资金将用于继续推进 Mentari 的靶向生物制剂产品管线的开发，旨在改善偏头痛患者的治疗结局。

Key transaction details for the private placement include:

私募配售的关键交易细节包括：

The additional $200 million private placement consisted of common stock and pre-funded warrants to purchase common stock (the 'Private Placement').

额外的2亿美元私募配售由普通股和用于购买普通股的预融资认股权证组成（以下简称“私募配售”）。

Investors include Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management LP, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, BB Biotech, and other leading healthcare investors..

投资者包括 Fairmount、ADAR1 Capital Management、Venrock Healthcare Capital Partners、Sirenia Capital Management LP、Janus Henderson Investors、Blackstone Multi-Asset Investing、RTW Investments、Deep Track Capital、Vivo Capital、Commodore Capital、BB Biotech 以及其他领先的医疗健康领域投资者。

The financing, based on current plans, extends Mentari's cash runway into 2029 and through Phase 2a readouts on each of the two PACAP-targeted lead programs, including MT-002.  Additionally, it supports the clinical development of Mentari's broader migraine prevention pipeline.

根据当前计划，此次融资将把Mentari的现金跑道延长至2029年，并覆盖其两个针对PACAP的领先项目（包括MT-002）的2a期临床数据读出。此外，它还将支持Mentari更广泛的偏头痛预防产品管线的临床开发。

The Private Placement is expected to close immediately prior to the completion of Mentari's merger with InMed Pharmaceuticals, Inc. (Nasdaq:

预计本次非公开发行将在Mentari与InMed Pharmaceuticals, Inc.（纳斯达克：

INM

INM

) (the 'Merger') and concurrently with the previously announced $290 million private placement (the 'Initial Private Placement'). The combined company will continue to operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market under a new ticker symbol.

）（以下简称“合并”），并与此前宣布的2.9亿美元私募配售（以下简称“初始私募配售”）同时进行。合并后的公司将继续以Mentari Therapeutics的名称运营，并在纳斯达克资本市场以新的股票代码上市交易。

Following the completion of the Merger, the Initial Private Placement and the Private Placement, the estimated total number of shares of common stock outstanding of the combined company on an as-converted / as-exercised basis is expected to be approximately 601,195,812.

在合并、初始私募配售及私募配售完成后，按转换/行权基础计算，合并后公司的已发行普通股总数预计约为601,195,812股。

Jefferies, TD Cowen, Stifel and Guggenheim Securities, are acting as the placement agents.

杰富瑞、TD Cowen、Stifel 和 Guggenheim Securities 担任配售代理。

About Mentari Therapeutics

关于 Mentari Therapeutics

Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition that affects more than 1 billion people globally. Mentari's lead programs target PACAP, a newly validated target that is mechanistically independent from CGRP, one of the first migraine targets to yield clinical and commercial success.

Mentari Therapeutics 是一家生物技术公司，致力于开发用于预防偏头痛的疗法，旨在让患者摆脱这种致残性且治疗不足的神经系统疾病，该病在全球影响超过10亿人。Mentari 的核心项目靶向 PACAP，这是一个新近得到验证的靶点，其作用机制独立于 CGRP；CGRP 是首批在临床和商业上取得成功的偏头痛治疗靶点之一。

Mentari's pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody designed to inhibit these complementary pathways with potential to deliver superior outcomes for people with incomplete response to CGRP-targeted therapies.

Mentari 的管线包括 MT-001，一种旨在实现便捷皮下给药的抗 PACAP 单克隆抗体；以及 MT-002，一种抗 CGRP 和抗 PACAP 双特异性抗体，旨在抑制这些互补通路，有望为对 CGRP 靶向疗法反应不全的患者带来更优的疗效。

The company's programs were discovered by Paragon Therapeutics. Mentari is based in Waltham, MA. For more information, visit mentaritx.com..

帕拉贡治疗公司（Paragon Therapeutics）发现了该公司的项目。Mentari 总部位于马萨诸塞州沃尔瑟姆。欲了解更多信息，请访问 mentaritx.com。

Forward-Looking Statements

前瞻性陈述

This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the proposed merger of InMed Pharmaceuticals Inc.

本新闻稿包含经修订的《1933年证券法》（“《证券法》”）第27A条和经修订的《1934年证券交易法》第21E条所指的“前瞻性陈述”，包括但不限于关于InMed Pharmaceuticals Inc.拟议合并的陈述。

('InMed') and Mentari Therapeutics, Inc. ('Mentari') and related private financing; the expected timing, completion and anticipated benefits of the merger and private financing; the expected proceeds from investors in the private financing; expectations regarding the use of proceeds, the sufficiency of resources to support the advancement of Mentari's pipeline through certain milestones and the time period over which resources will be sufficient to fund Mentari's anticipated operations; the combined company operating under the name Mentari Therapeutics, Inc.; the anticipated timing of regulatory filings for, and the development, potential benefits and therapeutic potential of, MT-001 and MT-002; and the strategy, plans, objectives and leadership of Mentari and the combined company.

（“InMed”）与Mentari Therapeutics, Inc.（“Mentari”）以及相关私募融资；合并及私募融资的预期时间安排、完成情况及预期收益；来自私募融资投资者的预期收益；关于收益用途、支持Mentari产品管线推进至特定里程碑所需资源的充足性，以及资源足以资助Mentari预期运营的时间段的预期；合并后的公司将以Mentari Therapeutics, Inc.的名义运营；MT-001和MT-002的监管文件提交的预期时间、开发进展、潜在益处及治疗潜力；以及Mentari及合并后公司的战略、计划、目标和管理层。

Words such as 'anticipate,' 'believe,' 'expect,' 'intend,' 'plan,' 'potential,' 'will' and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the risk that the merger may not be completed on the anticipated timeline or at all; the failure to obtain the required InMed shareholder and Mentari stockholder approvals or to satisfy other closing conditions, including effectiveness of the registration statement on Form S-4; the risk that any concurrent financing is not completed on the expected terms or.

“anticipate”（预期）、“believe”（相信）、“expect”（期望）、“intend”（打算）、“plan”（计划）、“potential”（潜在）、“will”（将）等词语及类似表述用于识别前瞻性陈述。这些陈述基于当前的预期，并受各种风险和不确定性的影响，可能导致实际结果出现重大差异，其中包括但不限于：合并可能无法按预期时间表完成或根本无法完成的风险；未能获得InMed股东和Mentari股东的必要批准，或未能满足其他交割条件，包括S-4表格注册声明生效的风险；以及任何同步融资可能无法按预期条款完成的风险。

No Offer or Solicitation

无要约或招揽

This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, or the solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本新闻稿仅供信息参考，不构成出售任何证券的要约，也不构成购买任何证券要约的招揽，亦不构成对任何投票或批准的招揽；在任何司法管辖区，若根据该司法管辖区的证券法，在注册或资格认定之前进行此类要约、招揽或销售属于违法行为，则不得在该司法管辖区进行任何证券销售。

Without limiting the foregoing, this press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in connection with any private placement or other financing by Mentari or InMed. Any such securities have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

在不限制前述内容的前提下，本新闻稿不构成出售要约，也不构成购买任何与 Mentari 或 InMed 进行的私募配售或其他融资相关的证券的要约邀请。此类证券尚未且将不会根据《证券法》或任何州证券法律进行注册，除非经过注册或适用注册豁免，否则不得在美国境内提供或销售。

No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an applicable exemption therefrom..

除通过符合《证券法》第10条要求的招股说明书或适用豁免的情形外，不得进行任何证券发行。

Important Additional Information About the Merger and Where to Find It

关于合并的重要补充信息及查阅方式

In connection with the proposed merger, InMed has filed with the SEC a registration statement on Form S-4 that includes a preliminary proxy statement/prospectus of InMed and a management information circular and will file other relevant documents with the SEC and applicable Canadian securities regulators.

就拟议的合并事宜，InMed已向美国证券交易委员会（SEC）提交了一份S-4表格注册声明，其中包含InMed的初步委托书/招股说明书以及管理层信息通告，并将向美国证券交易委员会及适用的加拿大证券监管机构提交其他相关文件。

The Form S-4 has not yet become effective. After the Form S-4 is declared effective, InMed will mail a definitive proxy statement/prospectus and management information circular to its shareholders and to Mentari's stockholders. INVESTORS AND SECURITYHOLDERS OF INMED AND MENTARI ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT/PROSPECTUS AND MANAGEMENT INFORMATION CIRCULAR (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS) AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT INMED, MENTARI, THE MERGER AND RELATED MATTERS.

S-4表格尚未生效。在S-4表格被宣布生效后，InMed公司将向其股东以及Mentari公司的股东邮寄最终的代理声明/招股说明书和管理信息通告。敦促InMed和Mentari的投资者及证券持有人，在S-4表格、代理声明/招股说明书和管理信息通告（包括所有修订和补充文件）以及向美国证券交易委员会（SEC）和加拿大证券监管机构提交或将要提交的所有其他相关文件可供查阅时，认真并完整地阅读这些文件，因为这些文件包含或将包含有关InMed、Mentari、合并及相关事项的重要信息。

Investors and securityholders may obtain free copies of these documents (when available) through the SEC's website at .

投资者和证券持有人可通过美国证券交易委员会（SEC）网站免费获取这些文件的副本（如有提供）。

www.sec.gov

www.sec.gov

, on SEDAR+ at

，在 SEDAR+ 上

www.sedarplus.ca

www.sedarplus.ca

, or from InMed at inmedpharma.com/investors.

，或从 InMed 官网 inmedpharma.com/investors 获取。

Participants in the Solicitation

招标参与者

InMed, Mentari and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from InMed's shareholders and Mentari's stockholders in connection with the proposed merger. Information regarding InMed's directors and executive officers and a description of their direct and indirect interests, by security holdings or otherwise, is set forth in InMed's most recent annual report [on Form 10-K / Form 40-F, as applicable] and its other filings with the SEC and on SEDAR+.

InMed、Mentari 及其各自的董事和高级管理人员可能被视为在与拟议合并相关的向 InMed 股东和 Mentari 股东征集委托书的事项中的参与者。有关 InMed 董事和高级管理人员的信息，以及他们通过证券持有或其他方式享有的直接和间接利益的描述，载于 InMed 最新的年度报告（视情况适用 Form 10-K 或 Form 40-F 格式）及其向美国证券交易委员会（SEC）和 SEDAR+ 提交的其他文件中。

Additional information regarding the participants and their interests is or will be contained in the proxy statement/prospectus and management information circular and other relevant materials filed or to be filed with the SEC and Canadian securities regulators. These documents may be obtained free of charge as described above..

有关参与者及其权益的更多信息，已包含或将包含在代理声明/招股说明书、管理层信息通函以及已向或即将向美国证券交易委员会（SEC）和加拿大证券监管机构提交的其他相关材料中。上述文件可按上文所述免费获取。

Media Contact

媒体联系人

Lia Dangelico

莉亚·丹杰利科

Deerfield Group

迪尔菲尔德集团

[email protected]

[email protected]

540-303-0180

540-303-0180

SOURCE Mentari Therapeutics

来源：Mentari Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示